On the stock market since 2007, it operates in the world of health and science. It has 915 employees. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit indicators sit around the sector average.
Clearly below the class average.
The price isn’t cheap next to earnings — that’s why this grade sits in the middle.
Clearly above the class average — a step short of the very top.
Clearly above the class average — a step short of the very top.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
The stock trades below its recent peak — about 11% off the top. A pullback, not a collapse.
The company sells $958.4M a year; the problem isn’t sales — it’s costs running above that number.
There is $983.6M in the vault; even if every debt were paid off, $629.2M would remain.
The average analyst price target is $688 — 29% above today’s price.
A loss of $288.3M against $958.4M in annual sales.
Over the last 12 months, executives reported 194 sells against just 41 buys. Not an alarm bell by itself, but a number worth watching.
On our five-subject report card, MDGL sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: MDGL has solid sales but closed last year at a loss. The road back to profit runs through spending discipline.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (50/100) says the stock isn’t cheap.